PNLIP and cholelithiasis: No increased occurrence of serious adverse events, such as pancreatitis, serious acute gallbladder disease, cholelithiasis, arrhythmias (despite an increase in heart rate), major depressive disorder or suicidal ideation, malignancies or death, was noted with tirzepatide.24 An asymptomatic elevation of pancreatic amylase by 19.55% and pancreatic lipase by 34.20% was recorded with tirzepatide, which did not translate into an increased occurrence of pancreatitis.